Lifeboat Foundation

Scientists say the system could be used to find ‘hidden gems’ of research and guide research funding allocations.

An artificial intelligence system trained on almost 40 years of the scientific literature correctly identified 19 out of 20 research papers that have had the greatest scientific impact on biotechnology – and has selected 50 recent papers it predicts will be among the ‘top 5%’ of biotechnology papers in the future.¹

Scientists say the system could be used to find ‘hidden gems’ of research overlooked by other methods, and even to guide decisions on funding allocations so that it will be most likely to target promising research.

Continue reading “Artificial intelligence system can predict the impact of research” »

As part of preparing for an experiment aboard the International Space Station, researchers explored new ways to culture living heart cells for microgravity research. They found that cryopreservation, a process of storing cells at-80°C, makes it easier to transport these cells to the orbiting lab, providing more flexibility in launch and operations schedules. The process could benefit other biological research in space and on Earth.

The investigation, MVP Cell-03, cultured heart precursor cells on the space station to study how microgravity affects the number of cells produced and how many of them survive. These precursor cells have potential for use in disease modeling, drug development, and regenerative medicine, such as using cultured heart cells to replenish those damaged or lost due to cardiac disease.

Previous studies suggest that culturing such cells in simulated microgravity increases the efficiency of their production. But using live cell cultures in space presents some unique challenges. The MVP Cell-03 experiment, for example, must be conducted within a specific timeframe, when the cells are at just the right stage. Flight changes and crew availability could lead to delays that affect the research.

Since the onset of the CRISPR genetic editing revolution, scientists have been working to leverage the technology in the development of gene drives that target pathogen-spreading mosquitoes such as Anopheles and Aedes species, which spread malaria, dengue and other life-threatening diseases.

Much less genetic engineering has been devoted to Culex genus mosquitoes, which spread devastating afflictions stemming from West Nile virus—the leading cause of mosquito-borne disease in the continental United States—as well as other viruses such as the Japanese encephalitis virus (JEV) and the pathogen causing avian malaria, a threat to Hawaiian birds.

Continue reading “Researchers create new CRISPR tools to help contain mosquito disease transmission” »

Europe’s medicines regulator on Friday backed the use of Pfizer’s COVID-19 vaccine for children as young as 12, paving the way for a broader roll-out in the region after similar clearances in the United States and Canada.

In March of 2014, I knew my eight year old daughter was sick. Once borderline overweight, she was now skeletally thin and fading away from us. A pre-dawn ambulance ride to the hospital gave us the devastating news – our daughter had Type 1 diabetes, and would be dependent on insulin injections for the rest of her life.

This news hit me particularly hard. I’ve always been a preparedness-minded kind of guy, and I’ve worked to free myself and my family from as many of the systems of support as possible. As I sat in the dark of the Pediatric ICU watching my daughter slowly come back to us, I contemplated how tied to the medical system I had just become. She was going to need a constant supply of expensive insulin, doled out by a medical insurance system that doesn’t understand that a 90-day supply of life-saving medicine is a joke to a guy who stocks a year supply of toilet paper. Plus I had recently read an apocalyptic novel where a father watches his 12-year old diabetic daughter slip into a coma as the last of her now-unobtainable insulin went bad in an off-grid world. I swore to myself that I’d never let this happen, and set about trying to find ways to make my own insulin, just in case.

Since the start of the pandemic, scientists have been seeking to better understand immunity to the novel coronavirus. How long is a person immune after having Covid-19, after getting vaccinated, or both? And what could long-lasting immunity mean for booster shots?

It’s still too early to tell — but experts are getting closer to cracking the code.

Researchers from Zurich have developed a compact, energy-efficient device made from artificial neurons that is capable of decoding brainwaves. The chip uses data recorded from the brainwaves of epilepsy patients to identify which regions of the brain cause epileptic seizures. This opens up new perspectives for treatment.

Current neural network algorithms produce impressive results that help solve an incredible number of problems. However, the electronic devices used to run these algorithms still require too much processing power. These artificial intelligence (AI) systems simply cannot compete with an actual brain when it comes to processing sensory information or interactions with the environment in real time.

Many people who have been infected with SARS-CoV-2 will probably make antibodies against the virus for most of their lives. So suggest researchers who have identified long-lived antibody-producing cells in the bone marrow of people who have recovered from COVID-19¹.

The study provides evidence that immunity triggered by SARS-CoV-2 infection will be extraordinarily long-lasting. Adding to the good news, “the implications are that vaccines will have the same durable effect”, says Menno van Zelm, an immunologist at Monash University in Melbourne, Australia.

Antibodies — proteins that can recognize and help to inactivate viral particles — are a key immune defence. After a new infection, short-lived cells called plasmablasts are an early source of antibodies.

It’s the rare individual who actually looks forward to getting jabbed with a needle, even if what’s in the needle can protect them from a serious disease such as COVID-19.

But several teams around the world are working on a way to inject a vaccine without the ouch. The trick is to make the needles small. Really small. So small they don’t interact with the nerve endings that signal pain.

Mark Prausnitz is director of the Center for Drug Design, Development and Delivery at Georgia Tech. He works on something called microneedle patches to deliver vaccines. So far, he’s developed patch vaccines for flu and measles, but the technology could be used for a COVID-19 vaccine as well.